{"blog": [], "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Actavis PLC", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "Salix Pharmaceuticals Ltd", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Pearson, John Michael (1959- )", "name": "persons", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/01/business/dealbook/valeant-chief-returns-to-a-difficult-to-do-list.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbWide.jpg", "legacy": {"wide": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/02/29/business/29valeant-web/29valeant-web-articleLarge.jpg", "legacy": {"xlarge": "images/2016/02/29/business/29valeant-web/29valeant-web-articleLarge.jpg", "xlargeheight": "395", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 395}, {"url": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "371", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "Even if the drug maker\u2019s delayed 2015 earnings are published soon, J. Michael Pearson\u2019s room for maneuvering is shrinking.", "pub_date": "2016-03-01T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "Valeant Chief Returns to a Difficult To-Do List", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "Even if the drug maker\u2019s delayed 2015 earnings are published soon, J. Michael Pearson\u2019s room for maneuvering is shrinking.", "_id": "56d4bb2c38f0d811294b8142", "slideshow_credits": null, "abstract": null}